Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IKZF2 | Q9UKS7 | 10/20 | 0.74 |
| ▸ | CRBN | Q96SW2 | 10/20 | 0.72 |
| ▸ | CSNK1A1 | P48729 | 2/20 | 0.67 |
| ▸ | IKZF1 | Q13422 | 1/20 | 0.57 |
| ▸ | GSPT1 | P15170 | 1/20 | 0.56 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.56 |
| ▸ | IKZF3 | Q9UKT9 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25571538 | 1.00 | IKZF2 (0.74) | IKZF2CRBNCSNK1A1IKZF1GSPT1 | |
| SCHEMBL29547357 | 1.00 | IKZF2 (0.74) | IKZF2CRBNCSNK1A1IKZF1GSPT1 | |
| SCHEMBL19503631 | 0.91 | CRBN (0.69) | IKZF2CRBNCSNK1A1GSPT1DDB1 | |
| SCHEMBL23226142 | 0.89 | CRBN (0.70) | IKZF2CRBNCSNK1A1GSPT1DDB1 | |
| SCHEMBL31546799 | 0.88 | CRBN (0.72) | IKZF2CRBNCSNK1A1GSPT1DDB1 | |
| SCHEMBL23729630 | 0.88 | CRBN (0.72) | IKZF2CRBNCSNK1A1GSPT1DDB1 | |
| SCHEMBL19503565 | 0.87 | IKZF2 (0.73) | IKZF2CRBNCSNK1A1DDB1 | |
| SCHEMBL24637334 | 0.87 | CRBN (0.71) | IKZF2CRBNCSNK1A1GSPT1DDB1 | |
| SCHEMBL25628768 | 0.87 | CRBN (0.74) | IKZF2CRBNCSNK1A1GSPT1DDB1 | |
| SCHEMBL23535299 | 0.86 | CRBN (0.74) | IKZF2CRBNCSNK1A1GSPT1DDB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12559486-B2 | Tau-protein targeting compounds and associated methods of use | ARVINAS OPERATIONS, INC. (US) | 2026-02-24 | — | — | US | disclosed |
| US-20240217962-A1 | TAU-PROTEIN TARGETING COMPOUNDS AND ASSOCIATED METHODS OF USE | ARVINAS OPERATIONS, INC. | 2024-07-04 | — | — | US | disclosed |
| US-11912699-B2 | Tau-protein targeting compounds and associated | ARVINAS OPERATIONS, INC. (US) | 2024-02-27 | — | — | US | disclosed |
| US-11912699-B2 | Tau-protein targeting compounds and associated | ARVINAS OPERATIONS, INC. (US) | 2024-02-27 | — | — | US | disclosed |
| US-11912699-B2 | Tau-protein targeting compounds and associated | ARVINAS OPERATIONS, INC. (US) | 2024-02-27 | — | — | US | disclosed |
| WO-2024006881-A1 | WEE1 DEGRADING COMPOUNDS AND USES THEREOF | BRISTOL-MYERS SQUIBB COMPANY (US) | 2024-01-04 | — | — | WO | disclosed |
| WO-2024006403-A2 | SELECTIVE HISTONE DEACETYLASE 8 (HDAC8) DEGRADERS AND METHODS OF USE THEREOF | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2024-01-04 | — | — | WO | disclosed |
| US-11833142-B2 | 3-(5-amino-1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof | NOVARTIS AG (CH) | 2023-12-05 | — | — | US | disclosed |
| WO-2023220722-A2 | PAK1 DEGRADERS AND METHODS OF USE THEREOF | INSTITUTE FOR CANCER RESEARCH D/B/A THE RESEARCH INSTITUTE OF FOX CHASE CANCER CENTER (US) | 2023-11-16 | — | — | WO | disclosed |
| EP-3820574-B1 | 3-(5-AMINO-1-OXOISOINDOLIN-2-YL)PIPERIDINE-2,6-DIONE DERIVATIVES AND THEIR USE IN THE TREATMENT OF IKAROS FAMILY ZINC FINGER 2 (IKZF2)-DEPENDENT DISEASES | NOVARTIS AG (CH) | 2023-08-09 | — | — | EP | disclosed |
| WO-2021242982-A1 | GALECTIN-3 INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2021-12-02 | — | — | WO | disclosed |
| WO-2021222542-A1 | 5-AMINO-2-PIPERIDINON-3-YL-1-OXOISOINDOLINE DERIVATIVES FOR DEGRADATION OF IKZF2 DEGRADERS | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2021-11-04 | — | — | WO | disclosed |
| WO-2021078301-A1 | PROTEIN DEGRADING AGENT AND USE THEREOF IN TREATMENT OF DISEASES | 上海科技大学 | 2021-04-29 | — | — | WO | disclosed |
| WO-2021068380-A1 | PREPARATION OF DEGRADATION COMPOUND TARGETING BTK PROTEIN, AND APPLICATION THEREOF IN TREATING AUTOIMMUNE DISEASES AND TUMORS | 清华大学 | 2021-04-15 | — | — | WO | disclosed |
| WO-2020227325-A1 | HETEROBIFUNCTIONAL COMPOUNDS AS DEGRADERS OF HPK1 | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (US) | 2020-11-12 | — | — | WO | disclosed |
| WO-2020081880-A1 | COMPOSITIONS TARGETING SENESCENT CELLS AND THE USES THEREOF | BIOVENTURES, LLC (US) | 2020-04-23 | — | — | WO | disclosed |
| WO-2020038415-A1 | TROPOMYOSIN RECEPTOR KINASE (TRK) DEGRADATION COMPOUNDS AND METHODS OF USE | CULLGEN (SHANGHAI), INC. (CN) | 2020-02-27 | — | — | WO | disclosed |
| WO-2019173516-A1 | SERINE THREONINE KINASE (AKT) DEGRADATION / DISRUPTION COMPOUNDS AND METHODS OF USE | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (US) | 2019-09-12 | — | — | WO | disclosed |
| WO-2019165189-A1 | PROTEIN ARGININE METHYLTRANSFERASE 5 (PRMT5) DEGRADATION / DISRUPTION COMPOUNDS AND METHODS OF USE | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (US) | 2019-08-29 | — | — | WO | disclosed |
| WO-2017184995-A1 | COMPOUNDS THAT INDUCE DEGRADATION OF ANTI-APOPTOTIC BCL-2 FAMILY PROTEINS AND THE USES THEREOF | BIOVENTURES, LLC (US) | 2017-10-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11912699-B2 | Tau-protein targeting compounds and associated | MAPT, VHL, CRBN | IKZF2 3079/4885CRBN 3/4885CSNK1A1 868/4885 |
| US-20240217962-A1 | TAU-PROTEIN TARGETING COMPOUNDS AND ASSOCIATED METHODS OF USE | VHL, CRBN, MAPT | IKZF2 3413/4885CRBN 2/4885CSNK1A1 829/4885 |
| US-11833142-B2 | 3-(5-amino-1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof | RXFP3, RXFP1, NPY2R | IKZF2 3369/4885CRBN 3123/4885CSNK1A1 486/4885 |
| US-12559486-B2 | Tau-protein targeting compounds and associated methods of use | UBQLN2, UBQLN1, CRBN | IKZF2 3718/4885CRBN 3/4885CSNK1A1 281/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.